Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics’ large shareholder group BVF and related entities reported a significant secondary-market sale and updated their ownership. On June 26, 2026, BVF-affiliated funds and a managed account sold an aggregate 1,630,658 Kymera shares at $106.50 per share.
After these trades, BVF, BVF2, Biotechnology Value Trading Fund OS and the Partners Managed Account together beneficially own 5,237,151 shares, or approximately 6.3% of Kymera’s common stock, based on 82,257,588 shares outstanding as of April 24, 2026 plus shares underlying certain pre-funded warrants.
The group holds 1,365,099 pre-funded warrants with a de minimis $0.0001 exercise price that do not expire, subject to a 9.99% ownership cap and Hart-Scott-Rodino thresholds. Director Gorjan Hrustanovic’s board-related stock options, covering 116,190 shares vesting within 60 days, are subject to an agreement assigning their economic benefit to BVF Partners.
KYMR proposed a sale of 1,630,658 shares of Common Stock, recorded on 06/26/2026. The shares were acquired upon automatic conversion in connection with the issuer's IPO on 08/21/202003/11/2020
The filing lists $189,906,430.68 alongside the security line and indicates trading on NASDAQ. The filer name shown is Jefferies LLC at 520 Madison Ave, New York.
KYMR submitted a Form 144 notice disclosing proposed sales of Common Stock by several selling holders, including multiple sales by Atlas Venture Fund X, L.P. and affiliates between 04/15/2026 and 06/25/2026
The excerpt lists individual sale dates, share quantities, and gross proceeds for each transaction (for example, 480,992 shares for $57,122,898.52 on 06/25/2026). These are routine resale notices under applicable securities rules.
KYMR notice reports multiple proposed sales of Common Stock by affiliated holders, showing specific sale dates, share quantities, and gross proceeds. The excerpt lists numerous sales by Atlas Venture Fund X, L.P. and related holders, including large transactions on 06/25/2026.
Kymera Therapeutics, Inc. reported that entities associated with director Bruce Booth sold a total of 285,684 shares of Kymera common stock on June 25 in open-market transactions. The sales were executed by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, and are reported as indirect interests, with Booth disclaiming Section 16 beneficial ownership except for any pecuniary interest.
Kymera Therapeutics, Inc. director-affiliated funds reported sizable open-market sales of common stock. Venture funds associated with director Bruce Booth sold a combined 398,765 shares of Kymera common stock in 30 open-market transactions from June 23–25, 2026. The trades were executed through Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported sale prices were weighted averages, with individual trades occurring in ranges from about $99.95 to $119.0789 per share. Booth is a member of the general partners of these funds and disclaims Section 16 beneficial ownership except for any pecuniary interest.
Kymera Therapeutics, Inc. had a group of BVF-affiliated reporting persons update their ownership in its securities. The only new transaction was an indirect grant of 6,068 stock options linked to common stock at an exercise price of $99.8700 per share.
These options expire on June 23, 2036 and vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. The filing also restates existing holdings in common shares, previously granted stock options, and pre-funded warrants that are exercisable at $0.0001 per share and do not expire.
Kymera Therapeutics, Inc. director Bruce Booth received a grant of stock options covering 6,068 shares of common stock. The options carry an exercise price of $99.87 per share and expire on June 23, 2036.
These options vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. Following this grant, Booth holds options for 6,068 shares. According to the disclosure, proceeds from any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Booth disclaims ownership except to the extent of any pecuniary interest.
Kymera Therapeutics director Gorjan Hrustanovic reported receiving a grant of stock options covering 6,068 shares of Common Stock. The options carry an exercise price of $99.87 per share and expire on June 23, 2036.
The underlying 6,068 shares vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. According to the disclosure, Hrustanovic is a member of BVF Partners L.P. and is obligated to transfer any economic benefit from the sale of shares issued upon exercise of these grants to BVF, and he disclaims beneficial ownership except to the extent of any pecuniary interest.
Kymera Therapeutics Chief Business Officer Noah Goodman reported an exercise-and-sell transaction in company stock. He exercised stock options for 5,000 shares of Common Stock at an exercise price of $21.05 per share, then sold 5,000 shares in two open-market sales at prices of $119.00 and $109.00 per share.
After these transactions, he directly holds 50,195.438 shares of Common Stock and 90,000 stock options. The filing notes that the sales were effected under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025.